NXTM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NXTM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. NxStage Medical's Total Stockholders Equity for the quarter that ended in Sep. 2018 was $225.2 Mil. NxStage Medical's Total Assets for the quarter that ended in Sep. 2018 was $377.4 Mil. Therefore, NxStage Medical's Equity to Asset Ratio for the quarter that ended in Sep. 2018 was 0.60.
The historical rank and industry rank for NxStage Medical's Equity-to-Asset or its related term are showing as below:
The historical data trend for NxStage Medical's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NxStage Medical Annual Data | |||||||||||||||||||||
Trend | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | |||||||||||
Equity-to-Asset | Get a 7-Day Free Trial | 0.63 | 0.62 | 0.63 | 0.64 | 0.66 |
NxStage Medical Quarterly Data | ||||||||||||||||||||
Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.66 | 0.66 | 0.66 | 0.66 | 0.60 |
For the Medical Instruments & Supplies subindustry, NxStage Medical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, NxStage Medical's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where NxStage Medical's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
NxStage Medical's Equity to Asset Ratio for the fiscal year that ended in Dec. 2017 is calculated as
Equity to Asset (A: Dec. 2017 ) | = | Total Stockholders Equity | / | Total Assets |
= | 213.158 | / | 325.629 | |
= | 0.65 |
NxStage Medical's Equity to Asset Ratio for the quarter that ended in Sep. 2018 is calculated as
Equity to Asset (Q: Sep. 2018 ) | = | Total Stockholders Equity | / | Total Assets |
= | 225.192 | / | 377.449 | |
= | 0.60 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NxStage Medical (NAS:NXTM) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of NxStage Medical's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Earl R Lewis | director | C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843 |
Craig W Moore | director | C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843 |
Jeffrey H Burbank | director, officer: Chief Executive Officer | NXSTAGE MEDICAL INC, 439 SOUTH UNION STREET 5TH FLOOR, LAWRENCE MA 01843 |
James J Peters | director | C/O NXSTAGE MEDICAL, INC., 350 MERRIMACK STREET, LAWRENCE MA 01843 |
Heyward R Donigan | director | 452 DISCOVERY ROAD, VIRGINIA BEACH VA 23451 |
Jean K Mixer | director | C/O NXSTAGE MEDICAL, INC., 350 MERRIMACK STREET, LAWRENCE MA 01843 |
Kevin Hershberger | officer: Chief Accounting Officer | 350 MERRIMACK STREET, LAWRENCE MA 01843 |
Philippe O. Chambon | director | C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036 |
Deerfield Management Company, L.p. (series C) | 10 percent owner, other: Possible Member of 10% Group | 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010 |
Deerfield Mgmt L.p. | 10 percent owner, other: Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Deerfield Partners, L.p. | 10 percent owner, other: Possible Member of 10% Group | 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010 |
James E Flynn | 10 percent owner, other: Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Deerfield Special Situations Fund, L.p. | 10 percent owner, other: Possible Member of 10% Group | 780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Deerfield International Master Fund, L.p. | 10 percent owner, other: Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Deerfield Special Situations International Master Fund, L.p. | 10 percent owner, other: Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
From GuruFocus
By GuruFocus Research GuruFocus Editor • 02-18-2011
By GuruFocus Research GuruFocus Editor • 11-19-2010
By GuruFocus Research GuruFocus Editor • 12-17-2010
By GuruFocus Research GuruFocus Editor • 10-13-2010
By GuruFocus Research GuruFocus Editor • 03-18-2011
By GuruFocus Research GuruFocus Editor • 02-18-2011
By GuruFocus Research GuruFocus Editor • 09-17-2010
By Marketwired Marketwired • 12-04-2018
By GuruFocus Research GuruFocus Editor • 11-19-2010
By GuruFocus Research GuruFocus Editor • 07-15-2010
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.